Rapid estrogen receptor signaling mediates estrogen-induced inhibition of vascular smooth muscle cell proliferation

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 33, Issue 8, 2013, Pages 1837-1843

  Ueda, Kazutaka ^a   Lu, Qing ^a   Baur, Wendy ^a   Aronovitz, Mark J ^a   Karas, Richard H ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

Cardiovascular diseases; Hormones; Molecular biology; Signal transduction

Indexed keywords

CYCLINE; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; MESSENGER RNA; PEPTIDE; PHOSPHOPROTEIN PHOSPHATASE 2A; PLATELET DERIVED GROWTH FACTOR; PROTEIN KINASE B;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; ATHEROSCLEROSIS; CAROTID ARTERY; CELL PROLIFERATION; COMPLEX FORMATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESTENOSIS; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; VASCULAR SMOOTH MUSCLE CELL; WILD TYPE;

CARDIOVASCULAR DISEASES; HORMONES; MOLECULAR BIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ATHEROSCLEROSIS; CALMODULIN-BINDING PROTEINS; CELL MOVEMENT; CELL PROLIFERATION; ESTROGEN RECEPTOR ALPHA; ESTROGENS; FEMALE; MEMBRANE PROTEINS; MICE; MICE, TRANSGENIC; MUSCLE, SMOOTH, VASCULAR; NERVE TISSUE PROTEINS; PEPTIDE FRAGMENTS; PHOSPHOPROTEIN PHOSPHATASES; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 84881027754     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.112.300752     Document Type: Article

References (32)

1. Miniño AM, Murphy SL, Xu J, Kochanek KD. Deaths: final data for 2008. Natl Vital Stat Rep. 2011;59: 1-126.
2. Mendelsohn ME, Karas RH. Molecular and cellular basis of cardiovascular gender differences. Science. 2005;308: 1583-1587.
3. Falkeborn M, Persson I, Adami HO, Bergström R, Eaker E, Lithell H, Mohsen R, Naessén T. The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement. Br J Obstet Gynaecol. 1992;99: 821-828.
4. Sellers TA, Mink PJ, Cerhan JR, Zheng W, Anderson KE, Kushi LH, Folsom AR. The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer. Ann Intern Med. 1997;127: 973-980.
5. Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, Hennekens CH. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. N Engl J Med. 1991;325: 756-762.
6. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, Trevisan M, Black HR, Heckbert SR, Detrano R, Strickland OL, Wong ND, Crouse JR, Stein E, Cushman M; Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 2003;349: 523-534.
7. Iafrati MD, Karas RH, Aronovitz M, Kim S, Sullivan TR Jr, Lubahn DB, O'Donnell TF Jr, Korach KS, Mendelsohn ME. Estrogen inhibits the vascular injury response in estrogen receptor alpha-deficient mice. Nat Med. 1997;3: 545-548.
8. Pare G, Krust A, Karas RH, Dupont S, Aronovitz M, Chambon P, Mendelsohn ME. Estrogen receptor-alpha mediates the protective effects of estrogen against vascular injury. Circ Res. 2002;90: 1087-1092.
9. Sullivan TR Jr, Karas RH, Aronovitz M, Faller GT, Ziar JP, Smith JJ, O'Donnell TF Jr, Mendelsohn ME. Estrogen inhibits the response-toinjury in a mouse carotid artery model. J Clin Invest. 1995;96: 2482-2488.
10. Sivritas D, Becher MU, Ebrahimian T, Arfa O, Rapp S, Bohner A, Mueller CF, Umemura T, Wassmann S, Nickenig G, Wassmann K. Antiproliferative effect of estrogen in vascular smooth muscle cells is mediated by Kruppellike factor-4 and manganese superoxide dismutase. Basic Res Cardiol. 2011;106: 563-575.
11. Yuan Y, Xu J. Loss-of-function deletion of the steroid receptor coactivator- 1 gene in mice reduces estrogen effect on the vascular injury response. Arterioscler Thromb Vasc Biol. 2007;27: 1521-1527.
12. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med. 1999;340: 1801-1811.
13. Karas RH, Hodgin JB, Kwoun M, Krege JH, Aronovitz M, Mackey W, Gustafsson JA, Korach KS, Smithies O, Mendelsohn ME. Estrogen inhibits the vascular injury response in estrogen receptor beta-deficient female mice. Proc Natl Acad Sci U S A. 1999;96: 15133-15136.
14. Mendelsohn ME, Karas RH. Rapid progress for non-nuclear estrogen receptor signaling. J Clin Invest. 2010;120: 2277-2279.
15. Björnström L, Sjöberg M. Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes. Mol Endocrinol. 2005;19: 833-842.
16. Le Romancer M, Treilleux I, Leconte N, Robin-Lespinasse Y, Sentis S, Bouchekioua-Bouzaghou K, Goddard S, Gobert-Gosse S, Corbo L. Regulation of estrogen rapid signaling through arginine methylation by PRMT1. Mol Cell. 2008;31: 212-221.
17. Ganz P. Vasomotor and vascular effects of hormone replacement therapy. Am J Cardiol. 2002;90(1A):11F-16F.
18. Darblade B, Pendaries C, Krust A, Dupont S, Fouque MJ, Rami J, Chambon P, Bayard F, Arnal JF. Estradiol alters nitric oxide production in the mouse aorta through the alpha-, but not beta-, estrogen receptor. Circ Res. 2002;90: 413-419.
19. Lu Q, Pallas DC, Surks HK, Baur WE, Mendelsohn ME, Karas RH. Striatin assembles a membrane signaling complex necessary for rapid, nongenomic activation of endothelial NO synthase by estrogen receptor alpha. Proc Natl Acad Sci U S A. 2004;101: 17126-17131.
20. Bernelot Moens SJ, Schnitzler GR, Nickerson M, Guo H, Ueda K, Lu Q, Aronovitz MJ, Nickerson H, Baur WE, Hansen U, Iyer LK, Karas RH. Rapid estrogen receptor signaling is essential for the protective effects of estrogen against vascular injury. Circulation. 2012;126: 1993-2004.
21. Millward TA, Zolnierowicz S, Hemmings BA. Regulation of protein kinase cascades by protein phosphatase 2A. Trends Biochem Sci. 1999;24: 186-191.
22. Janssens V, Goris J, Van Hoof C. PP2A: the expected tumor suppressor. Curr Opin Genet Dev. 2005;15: 34-41.
23. Junttila MR, Puustinen P, Niemelä M, et al. CIP2A inhibits PP2A in human malignancies. Cell. 2007;130: 51-62.
24. Chen W, Possemato R, Campbell KT, Plattner CA, Pallas DC, Hahn WC. Identification of specific PP2A complexes involved in human cell transformation. Cancer Cell. 2004;5: 127-136.
25. Lu Q, Surks HK, Ebling H, Baur WE, Brown D, Pallas DC, Karas RH. Regulation of estrogen receptor alpha-mediated transcription by a direct interaction with protein phosphatase 2A. J Biol Chem. 2003;278: 4639-4645.
26. Turgeon JL, McDonnell DP, Martin KA, Wise PM. Hormone therapy: physiological complexity belies therapeutic simplicity. Science. 2004;304: 1269-1273.
27. Nilsson S, Koehler KF. Oestrogen receptors and selective oestrogen receptor modulators: molecular and cellular pharmacology. Basic Clin Pharmacol Toxicol. 2005;96: 15-25.
28. Chambliss KL, Wu Q, Oltmann S, et al. Non-nuclear estrogen receptor alpha signaling promotes cardiovascular protection but not uterine or breast cancer growth in mice. J Clin Invest. 2010;120: 2319-2330.
29. Castoria G, Migliaccio A, Giovannelli P, Auricchio F. Cell proliferation regulated by estradiol receptor: therapeutic implications. Steroids. 2010;75: 524-527.
30. Acconcia F, Kumar R. Signaling regulation of genomic and nongenomic functions of estrogen receptors. Cancer Lett. 2006;238: 1-14.
31. Takeda-Matsubara Y, Nakagami H, Iwai M, Cui TX, Shiuchi T, Akishita M, Nahmias C, Ito M, Horiuchi M. Estrogen activates phosphatases and antagonizes growth-promoting effect of angiotensin II. Hypertension. 2002;39: 41-45.
32. Yang L, Wang Y, Chen P, Hu J, Xiong Y, Feng D, Liu H, Zhang H, Yang H, He J. Na(+)/H(+) exchanger regulatory factor 1 (NHERF1) is required for the estradiol-dependent increase of phosphatase and tensin homolog (PTEN) protein expression. Endocrinology. 2011;152: 4537-4549.